Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559 at 2025 ASCO Annual Meeting

Accent Therapeutics Logo (PRNewsfoto/Accent Therapeutics)

ATX-559, a first-in-class oral DHX9 inhibitor, is being evaluated in a Phase 1/2 study with a focus

on advanced or metastatic patients with BRCA-1 and/or BRCA-2-deficient breast cancer or

Recommended for you